Skip to main content
. 2012 Oct 17;2012:845672. doi: 10.1155/2012/845672

Figure 3.

Figure 3

Colonic mucosal NF-κB protein expression in the control group, UC model group, and rosiglitazone treated group on days 7, 14, 21, 35. In the control group, expression of NF-κB protein in the colonic mucosa was significantly less compared to the UC model group (P < 0.05). In the rosiglitazone treatment group, NF-κB protein expression reduced significantly than that of the model group on days 7, 14, 21, and 35 (P < 0.05).